The Use of Radiology Imaging in Monitoring Treatment Response to PD-1/PD-L1 Inhibitors in Head and Neck Squamous Cell Carcinomas

Interdisciplinary cancer research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New

Hematology Reports, Journal Year: 2025, Volume and Issue: 17(3), P. 23 - 23

Published: April 28, 2025

Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare and aggressive non-Hodgkin (NHL), considered specific entity with proper characteristics, therapies, prognosis. First-line treatment not unique, subsequent strategies in case of disease persistence or relapse are the subject debate studies. In this scenario, [18F]FDG PET/CT plays pivotal role both characterizing mass, main feature PMLBCL, staging, restaging during therapy (interim PET), at end (EoT to guide clinical management give prognostic insights. The issue PMLBCL distinguishing viable from residual fibrotic/inflammatory mass after and, consequently, settling next strategy. Novel therapeutic approaches ongoing associated deepening potentials as principal tool context. review, we will explore Nuclear Medicine point view help clinicians these patients.

Language: Английский

---

Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis

The Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: 231(2), P. 532 - 539

Published: Aug. 15, 2024

The role of 2-deoxy-2-18(F) fluoro-D-glucose (FDG) positron emission tomography (PET)-computed (CT) in assessing treatment response chronic pulmonary aspergillosis (CPA) remains to be determined. study objective was compare FDG-PET/CT parameters persons with CPA achieving success or failure after 6 months oral itraconazole. We performed PET-CT at baseline and itraconazole therapy. FDG uptake similar the background ≥13 units decline Z-score considered a complete metabolic (CMR). A >25%, >30%, > 45% standardised value (SUVmax), SUVpeak, total glycolytic activity (TLG) labelled as partial (PMR). >75% increase SUVmax, TLG represented progressive disease. included 94 (63 male) mean age 46.2 years. follow-up on 77 participants. recorded 43 34 patients. CMR seen 18.6% those none failure. higher proportion patients achieved PMR; 19% had Most improved treatment; however, misclassified one-fifth

Language: Английский

---

Clinicians’ perspectives on PET/CT in oncological patients: an Italian National Survey

Clinical and Translational Imaging, Journal Year: 2023, Volume and Issue: 12(1), P. 99 - 107

Published: Aug. 26, 2023

Abstract Introduction The present web-based national survey aims to assess the clinician's perspective toward (1) indications perform positron emission tomography/computed tomography (PET/CT) in cancer patients, (2) utility of interaction with referring nuclear medicine physician, and (3) their perception clarity, usefulness, impact PET/CT report. Methods We conducted a prospective consisting 31 multiple-choice questions an open-text field. questionnaire was administered Italian clinicians or surgeons who managed oncological patients. Data were analyzed using standard diagrams values expressed as numbers (percentages). Results A total 373 physicians completed questionnaire. Among 360 responses finally included analysis, majority came from radiation oncologists (46%), followed by oncologists. For half respondents (53%), examination “often” clear easily accessible, but only 16% considered them “absolutely” accessible. Additionally, most (43%) necessary facilitate access update. physician generally useful satisfying. Regarding report, 74% standardize report structure, presence semi-quantitative parameters great importance. Finally, about cases impacts patient management major changes. Conclusion To sum up, “still not” complete confidence need update emerged our results. Moreover, structured clarification on essential PET features is warranted. In this scenario, participation guideline committees, international conferences well continuous training among all specialists involved patients’ could be effective strategies resolve clinicians' concerns PET/CT, thereby improving

Language: Английский

---

Transformative Precision: Investigative Summary of PET/CT-Guided Radiation Therapy Simulation in Comprehensive Cancer Management

European Journal of Theoretical and Applied Sciences, Journal Year: 2024, Volume and Issue: 2(1), P. 623 - 633

Published: Jan. 1, 2024

Positron Emission Tomography/Computed Tomography (PET/CT)-guided radiation therapy simulation has transformed cancer treatment, ushering in enhanced precision and individualization. This discussion delves into clinical indications, applications, procedures, limitations, providing a comprehensive overview across types. Clinical indications underscore PET/CT's role accurate staging, target volume delineation, treatment response assessment, post-treatment recurrence detection. Accurate staging is crucial for tailored plans, while delineation benefits from PET's identification of metabolic patterns. Ongoing assessment enables dynamic adjustments, post-treatment, PET/CT aids detecting recurrent disease. Applications highlight planning optimization by combining anatomical functional information. Fusion PET CT images customizes identifying active regions targeted delivery sparing healthy tissues. fusion facilitates strategies, minimizing exposure enabling adaptations. Procedural aspects detail imaging acquisition, image fusion, planning, ongoing monitoring. Starting with radiotracer administration, typically fluorodeoxyglucose (FDG), captures data. Image optimizing plans. monitoring allows real-time adjustments. Specific applications cancers demonstrate versatility. In head neck cancers, it ensures precise avoiding critical structures. lung cancer, improves tumor extent identification. Similar advantages apply to lymphomas, sarcomas, brain tumors, metastatic disease, esophageal, gastrointestinal, breast, prostate, gynecological, pediatric cancers. Limitations include spatial resolution challenges, false positives, cumulative exposure, lesion size, histology, standardization issues. research targets enhancement, radiomics AI integration, novel tracers, hybrid imaging, patient-specific dosimetry, trials, multimodal workflows, cost-effectiveness, accessibility, education. PET/CT-guided transformative. advancements promise more individualized approach, enhancing patient outcomes management.

Language: Английский

---

Prognostic Role of Pre- and Post-Treatment [18F]FDG PET/CT in Squamous Cell Carcinoma of the Oropharynx in Patients Treated with Chemotherapy and Radiotherapy

Medical Sciences, Journal Year: 2024, Volume and Issue: 12(3), P. 36 - 36

Published: July 29, 2024

Background: The prognostic role of imaging with [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in oropharynx cancer (OPC) has been demonstrated the past. aim this study was to assess impact both baseline and post-treatment PET/CT patients OPC treated chemo- and/or radiotherapy. Methods: parameters scans performed before after therapy were collected analyzed find significant prognosticators for progression-free survival (PFS) overall (OS). Human papillomavirus (HPV) infection’s influence on prognosis also taken into account. Results: A total 66 included study. staging volumetric OS, while same affordable predictors PFS at restaging evaluation. No correlations between HPV infection reported. Conclusion: [18F]FDG

Language: Английский

---

Radiographic Response Assessments and Standardized Imaging Interpretation Criteria in Head and Neck Cancer on FDG PET/CT: A Narrative Review

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2900 - 2900

Published: Aug. 21, 2024

Introduction: There is growing interest in the development and application of standardized imaging criteria (SIC), to minimize variability improve reproducibility image interpretation head neck squamous cell carcinoma (HNSCC). Methods: “Squamous carcinoma” AND “standardized criteria” OR “radiographic response assessment” were searched using PubMed Google Scholar for articles published between 2009 2024, returning 56 publications. After abstract review, 18 selected further evaluation, 6 different SICs (i.e., PERCIST, Porceddu, Hopkins, NI-RADS, modified Deauville, Cuneo) included this review. Each SIC evaluated context 8 desired traits a reporting system. Results: Two have societal endorsements NI-RADS); four can be used evaluation locoregional systemic disease Cuneo), specific categories equivocal results Cuneo). All demonstrated areas future improvement traits. Conclusion: Multiple been developed value HNSCC post-treatment imaging; however, these systems remain underutilized. Selecting an with features that best match needs one’s practice expected maximize likelihood successful implementation.

Language: Английский

---

Évaluation de la réponse thérapeutique par TEP-FDG des cancers solides (critères PERCIST 1.0)

Médecine Nucléaire, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

---